A modified QbD approach was used to develop a novel pediatric formulation.

Formulating Ezogabine for Children

Dosage-level authentication provides an added digital layer of security.

Securing Each Dose

Topical drugs are attractive to patients but pose challenges for formulators.

The Art and Science of Topical Drug Formulation

Topic

Articles

FDA has accepted Airway’s investigational new drug application for the development of its novel human recombinant protein, AT-100 (rhSP-D), as a treatment for COVID-19.

FDA Accepts IND for Airway Therapeutics’ Treatment for Severe COVID-19 Patients

Jennifer Markarian is manufacturing editor of Pharmaceutical Technology.

Intensified and distributed manufacturing approaches create flexible, local capacity.

Advanced Manufacturing Technologies Shift Outside the Box

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Topical drugs are attractive to patients, but these complex products pose challenges for formulators.

Balancing the Art and Science of Topical Drug Formulation

Editor of Pharmaceutical Technology Europe

Accelerated formulation strategies are a useful tool to reduce development timelines and cost, but key priorities must be considered early on to ensure success.

Focusing on Accelerated Formulation Strategies

Despite its importance in drug development, dissolution testing still has some limitations, but advances in automation and real-time monitoring are producing promising results.

Limitations and Advances in Dissolution Testing

Rita Peters is editorial director of Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm International.

Smart, accurate, science-based messaging is needed to advance bio/pharma science.

Avoiding Unforced Errors in the Bio/Pharma Industry

Aaron Stewart is associate principal scientist at Lonza Pharma and Biotech, Bend, OR.

In-vitro and in-silico tools can help predict in-vivo outcomes for low-solubility drugs formulated as spray-dried dispersions. 

Advancing Spray-Dried Dispersion Formulation Development

The companies will use Ajinomoto’s AJICAP proprietary site-specific bioconjugation technology for the development of Bright Peak’s Immunocytokines.

Ajinomoto and Bright Peak Therapeutics to Collaborate on Immunocytokines Development

The companies will aim to establish clinical and commercial supply agreements for Plus Therapeutics’ RNL-liposome drug product at the appropriate stage of development. 

Piramal Pharma Solutions to Provide Intermediate Drug Product Services to Plus Therapeutics 

The fund will focus on emerging life science companies with novel platforms and methods to improve therapeutic outcomes and those with technologies that support science research, development, and manufacturing.